

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 February 2024 (22.02.2024)



(10) International Publication Number
WO 2024/039897 A2

(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 9/20 (2006.01)

(21) International Application Number:

PCT/US2023/030689

(22) International Filing Date:

21 August 2023 (21.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/399,619 19 August 2022 (19.08.2022) US
63/400,640 24 August 2022 (24.08.2022) US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US];
3545 Cray Court, San Diego, CA 92121 (US).

(72) Inventors: **NUNES, Cletus**; c/o Mirati Therapeutics,
Inc., 3545 Cray Court, San Diego, CA 92121 (US).
KHEIRIPOUR, Mehrdad; c/o Mirati Therapeutics, Inc.,
3545 Cray Court, San Diego, CA 92121 (US). **GAVIRED-
DI, Monika**; c/o Mirati Therapeutics, Inc., 3545 Cray
Court, San Diego, CA 92121 (US).

(74) Agent: **POLYAKOV, Mark, V.** et al.; Wood, Phillips, Katz,
Clark & Mortimer, 500 West Madison Street, Suite 1130,
Chicago, IL 60661 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(54) Title: ADAGRASIB SOLID PHARMACEUTICAL COMPOSITIONS

(57) Abstract: Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer;
as well as methods of manufacturing the compositions, and methods of treating cancer.

WO 2024/039897 A2